Lupin to develop next-gen inhalers using Honeywell's Solstice Air propellant
Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. L
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
23 minutes ago
- Business Standard
Lupin launches Bosentan tablets for oral suspension in US market
Lupin announced the launch of Bosentan tablets for oral suspension, 32 mg in the United States, following approval received by its alliance partner, NATCO Pharma, from the US Food and Drug Administration (USFDA). According to an exchange filing, NATCO holds exclusive first-to-file status for the product and will benefit from 180-day generic drug exclusivity. The product is the bioequivalent to Tracleer Tablets for Oral Suspension, marketed by Actelion Pharmaceuticals US, Inc. Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. As per IQVIA MAT data for June 2025, Bosentan Tablets (RLD Tracleer) had estimated annual sales of approximately $10 million in the US market. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupins consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25. Shares of Lupin declined 0.61% to Rs 1,956.50 on the BSE, while shares of Natco Pharma slipped 0.82% to Rs 885.95 on the BSE.
Business Standard
26 minutes ago
- Business Standard
Lupin launches Bosentan Tablets for Oral Suspension 32 mg in US market
Lupin today announced the launch of Bosentan Tablets for Oral Suspension, 32 mg in the United States. This follows the approval received by Lupin's alliance partner, NATCO Pharma Limited (NATCO) for its Abbreviated New Drug Application from the United States Food and Drug Administration (U.S. FDA). NATCO holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity. Bosentan Tablets for Oral Suspension, 32 mg, are bioequivalent to Tracleer Tablets for Oral Suspension of Actelion Pharmaceuticals US, Inc. They are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan Tablets (RLD Tracleer) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2025).
The Hindu
12-08-2025
- The Hindu
Sandoz to market Lupin's biosimilar ranibizumab in multiple markets globally
Lupin on Tuesday announced a partnership with Swiss major Sandoz Group AG to market and commercialise its biosimilar ranibizumab across multiple regions. Sandoz will oversee commercialisation of the product across European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Ranibizumab is indicated in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR) and Choroidal Neovascularization (CNV). Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. It will also acquire sole rights for commercialisation of the biosimilar in Canada, while Lupin will manage the manufacture and regulatory filings.
